Home › NDC Lookup › RxCUI directory › RxCUI 2176321

0.3 ML bremelanotide 5.83 MG/ML Auto-Injector [Vyleesi] — RxCUI 2176321

RxNorm drug concept · Semantic branded drug
RxCUI 2176321 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2176321
Official name0.3 ML bremelanotide 5.83 MG/ML Auto-Injector [Vyleesi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as0.3 ML Vyleesi 5.83 MG/ML Auto-Injector; vyleesi 1.75 MG in 0.3 mL Auto-Injector; Vyleesi 1.75 MG (equivalent to bremelanotide acetate 1.89 MG) per 0.3 ML Auto-Injector; Vyleesi 1.75 MG per 0.3 ML Auto-Injector
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bremelanotide Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That means low desire that bothers you and isn't explained by another condition, re...
  • You inject it under the skin of your abdomen or thigh with the prefilled pen, at least 45 minutes before expected sexual activity. Use it only as needed. Don't take more than one d...
  • Nausea is the big one, affecting about 4 in 10 people in trials, though it often improves after the second dose. Flushing, headache, vomiting and injection site reactions can also...
  • If your blood pressure is uncontrolled or you have known cardiovascular disease, you should not use it. Vyleesi raises blood pressure for several hours after each dose. Your doctor...
📖 Read our full Bremelanotide Injection guide →

🕸️ Concept Web — How 0.3 ML bremelanotide 5.83 MG/ML Auto-Injector [V... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.3 ML bremelanotide 5.83 MG/ML Auto-Injector [Vyleesi] RxCUI 2176321

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bremelanotide 2176312
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vyleesi 2176317
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bremelanotide Auto-Injector 2176315
    • Bremelanotide Injectable Product 2176314
    • Bremelanotide Auto-Injector [Vyleesi] 2176319
    • Vyleesi Injectable Product 2176320
    • Auto-Injector 1649570
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Bremelanotide 5.83 MG/ML [Vyleesi] SBDC · 2176318
  • Bremelanotide Auto-Injector [Vyleesi] SBDF · 2176319
  • Vyleesi Injectable Product SBDG · 2176320
  • Vyleesi BN · 2176317

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2176321 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00713-0897-04 4 SYRINGE in 1 CARTON (0713-0897-04) / .3 mL in 1 SYRINGE (... Vyleesi Cosette Pharmaceuticals, Inc. 2025-11-12
Observed labelers: Cosette Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.